Association of BAX G(-248)A and BCL2 C(-717)A polymorphisms with outcome in diffuse large B-cell lymphoma patients

Br J Haematol. 2017 May;177(4):650-654. doi: 10.1111/bjh.14089. Epub 2016 Apr 21.
No abstract available

Keywords: BAX; BCL2; Diffuse large B-cell lymphoma; outcome; single nucleotide polymorphism.

Publication types

  • Letter

MeSH terms

  • Alleles*
  • Antibodies, Monoclonal, Murine-Derived / adverse effects
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cyclophosphamide / adverse effects
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / adverse effects
  • Doxorubicin / therapeutic use
  • Female
  • Genotype
  • Humans
  • Kaplan-Meier Estimate
  • Lymphoma, Large B-Cell, Diffuse / drug therapy
  • Lymphoma, Large B-Cell, Diffuse / genetics*
  • Lymphoma, Large B-Cell, Diffuse / mortality*
  • Lymphoma, Large B-Cell, Diffuse / pathology
  • Male
  • Polymorphism, Single Nucleotide*
  • Prednisone / adverse effects
  • Prednisone / therapeutic use
  • Prognosis
  • Proto-Oncogene Proteins c-bcl-2 / genetics*
  • Rituximab
  • Treatment Outcome
  • Vincristine / adverse effects
  • Vincristine / therapeutic use
  • bcl-2-Associated X Protein / genetics*

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Proto-Oncogene Proteins c-bcl-2
  • R-CHOP protocol
  • bcl-2-Associated X Protein
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone